Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 247 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Polycythemia Vera Clear all
Completed Phase 2 Interventional Results available

Study of SB939 in Subjects With Myelofibrosis

NCT01200498
View directory record Official record
Conditions
Myeloproliferative Disorders
Interventions
SB939
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2014 · Synced Oct 21, 2026, 2:09 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

NCT00509899
View directory record Official record
Conditions
Myelofibrosis, Polycythemia Vera, Thrombocytosis
Interventions
Ruxolitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
2
States / cities
Rochester, Minnesota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Oct 21, 2026, 2:09 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer

NCT00003816
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Nonmalignant Neoplasm, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
anti-thymocyte globulin, busulfan, carboplatin, cyclophosphamide, etoposide, fludarabine phosphate, melphalan, thiotepa, total-body irradiation
Biological · Drug · Radiation
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
4 Years to 70 Years
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2019
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 13, 2021 · Synced Oct 21, 2026, 2:09 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia

NCT00463385
View directory record Official record
Conditions
Myelofibrosis With Myeloid Metaplasia, Myeloid Metaplasia, Myelofibrosis
Interventions
Pomalidomide, Prednisone, Placebo to pomalidomide, Placebo to prednisone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
6
States / cities
Los Angeles, California • Rochester, Minnesota • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Oct 21, 2026, 2:09 PM EDT
Completed Phase 2 Interventional

A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders

NCT02125318
View directory record Official record
Conditions
Thrombocytosis, Myeloproliferative Neoplasms
Interventions
Anagrelide CR
Drug
Lead sponsor
Galena Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
11
States / cities
Burbank, California • Encinitas, California • Escondido, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 21, 2026, 2:09 PM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis

NCT03222609
View directory record Official record
Conditions
Myelofibrosis (MF)
Interventions
Ruxolitinib, Navitoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
33
States / cities
Birmingham, Alabama • Cerritos, California • Duarte, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 21, 2026, 2:09 PM EDT
Recruiting No phase listed Observational

MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)

NCT07362225
View directory record Official record
Conditions
Polycythemia Vera, ET (Essential Thrombocythemia), Polycythemia Vera (PV), Essential Thrombocythemia (ET), Primary Myelofibrosis (MF), Primary Myelofibrosis (PMF), Myelofibrosis, Myelofibrosis (MF), Myelofibrosis, Primary, Myelofibrosis, Post ET, Myelofibrosis, Post PV, Myelofibrosis (PMF), Myelofibrosis，MF, Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera, Myelofibrosis Transformation in Essential Thrombocythemia, Myelofibrosis With High Molecular Risk Mutations, MF, Secondary Myelofibrosis, Secondary Myelofibrosis in Myeloproliferative Disease, Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis), Post-Polycythemia Vera Myelofibrosis, Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), Post-polycythemia Vera Myelofibrosis(Post-PV MF), Post-PV MF, Post-Essential Thrombocythemia Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis (PET-MF), Post-essential Thrombocythemia Myelofibrosis(Post-ET MF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-ET MF, Pre-fibrotic Myelofibrosis, Myeloproliferative Disorder, Myeloproliferative Disorders, Myeloproliferative Disorders (MPD), Myeloproliferative Neoplasms (MPNs), Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis, Myeloproliferative Neoplasm With 10% Blasts or Higher, Myeloproliferative Neoplasms, MPN, MPN (Myeloproliferative Neoplasms), MPN-associated Myelofibrosis, Myeloproliferative Neoplasm, Unclassifiable, Myeloproliferative Neoplasm, Not Otherwise Specified, Accelerated Phase MPN, Accelerated Phase Myeloproliferative Neoplasm, Blast Phase MPN, Blast Phase Myeloproliferative Neoplasm, Thrombocythemia Myelofibrosis (PET-MF), Thrombocythemia, Essential, Thrombocythemia, Hemorrhagic, Agnogenic Myeloid Metaplasia, Chronic Idiopathic Myelofibrosis, Idiopathic Myelofibrosis, MDS/MPN Crossover Syndromes
Interventions
Not listed
Lead sponsor
MPN Research Foundation
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 21, 2026, 2:09 PM EDT
Completed Phase 1Phase 2 Interventional

Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder

NCT00054340
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, methotrexate, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 14, 2010 · Synced Oct 21, 2026, 2:09 PM EDT
Completed Phase 2 Interventional Results available

Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

NCT02515630
View directory record Official record
Conditions
Primary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV) Myelofibrosis, Postessential Thrombocythemia (Post-ET) Myelofibrosis
Interventions
MMB
Drug
Lead sponsor
Sierra Oncology LLC - a GSK company
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 21, 2026, 2:09 PM EDT
Completed Phase 3 Interventional Results available

Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF

NCT02101268
View directory record Official record
Conditions
Primary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
Interventions
Momelotinib, Best Available Therapy (BAT)
Drug
Lead sponsor
Sierra Oncology LLC - a GSK company
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
13
States / cities
Los Angeles, California • Gainesville, Florida • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Oct 21, 2026, 2:09 PM EDT
Terminated Phase 2 Interventional Results available

Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis

NCT02421354
View directory record Official record
Conditions
Hepatomegaly, Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis, Splenomegaly
Interventions
Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment
Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Oct 21, 2026, 2:09 PM EDT
Terminated Phase 1 Interventional

506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment

NCT00004239
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
Compound 506U78
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
3
States / cities
Chicago, Illinois • Iowa City, Iowa • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 4, 2016 · Synced Oct 21, 2026, 2:09 PM EDT
Completed Phase 1 Interventional

Stem Cell Transplantation in Treating Patients With Hematologic Cancer

NCT00004904
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Small Intestine Cancer
Interventions
anti-thymocyte globulin, filgrastim, cladribine, cyclophosphamide, etoposide, methylprednisolone, tacrolimus, allogeneic bone marrow transplantation, in vitro-treated peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
Up to 45 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Oct 21, 2026, 2:09 PM EDT
Terminated Phase 2 Interventional Results available

Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN)

NCT02410551
View directory record Official record
Conditions
Myeloproliferative Diseases
Interventions
Pacritinib, Busulfan, Questionnaires, Phone Calls, Allogeneic Stem Cell Transplantation, Fludarabine
Drug · Behavioral · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Oct 21, 2026, 2:09 PM EDT
Completed Phase 2 Interventional

Phase 2 Study of SAR302503 in Patients With Myelofibrosis

NCT01420770
View directory record Official record
Conditions
Hematopoietic Neoplasm
Interventions
SAR302503
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
4
States / cities
San Francisco, California • Ann Arbor, Michigan • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 21, 2026, 2:09 PM EDT
Terminated Phase 2 Interventional Results available

Imatinib Mesylate in Treating Patients With Myelofibrosis

NCT00245128
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders
Interventions
imatinib mesylate
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 13, 2012 · Synced Oct 21, 2026, 2:09 PM EDT
Completed Phase 1Phase 2 Interventional

Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation

NCT00052520
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Essential Thrombocythemia, Polycythemia Vera, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, T-cell Adult Acute Lymphoblastic Leukemia, T-cell Childhood Acute Lymphoblastic Leukemia
Interventions
therapeutic allogeneic lymphocytes, aldesleukin, peripheral blood stem cell transplantation, allogeneic bone marrow transplantation, laboratory biomarker analysis, gene expression analysis, immunologic technique, flow cytometry, polymerase chain reaction, cytogenetic analysis, staining method
Biological · Procedure · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 21, 2026, 2:09 PM EDT
Completed Phase 3 Interventional Results available

Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

NCT01259856
View directory record Official record
Conditions
High Risk Polycythemia Vera, High Risk Essential Thrombocythemia
Interventions
PEGASYS, Hydroxyurea, Aspirin
Drug
Lead sponsor
Ronald Hoffman
Other
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
16
States / cities
Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Oct 21, 2026, 2:09 PM EDT
Completed Phase 1 Interventional

MPN-RC 118 AVID200 in Myelofibrosis

NCT03895112
View directory record Official record
Conditions
Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post ET MF, Post PV MF
Interventions
AVID200
Drug
Lead sponsor
John Mascarenhas
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2023 · Synced Oct 21, 2026, 2:09 PM EDT
Recruiting Phase 2 Interventional

MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial

NCT06541249
View directory record Official record
Conditions
Polycythemia Vera (PV), Essential Thrombocythemia (ET), Myelofibrosis (MF)
Interventions
Methotrexate (MTX)
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 21, 2026, 2:09 PM EDT
Completed Phase 2 Interventional

Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer

NCT00002504
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
aldesleukin, recombinant interferon alfa
Biological
Lead sponsor
Hoag Memorial Hospital Presbyterian
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 1999
U.S. locations
5
States / cities
Newport Beach, California • Bloomington, Indiana • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated May 12, 2011 · Synced Oct 21, 2026, 2:09 PM EDT
Not listed Phase 1 Interventional

Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer

NCT00004036
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
sargramostim, amifostine trihydrate, carboplatin, cyclophosphamide
Biological · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 21, 2026, 2:09 PM EDT
Terminated Phase 2 Interventional Results available

Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors

NCT03627403
View directory record Official record
Conditions
Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis
Interventions
Selinexor
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 21, 2026, 2:09 PM EDT
Not listed Phase 1Phase 2 Interventional

LBH589 (Panobinostat) for the Treatment of Myelofibrosis

NCT01298934
View directory record Official record
Conditions
Primary Myelofibrosis, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Post-Essential Thrombocythemia Related Myelofibrosis
Interventions
LBH589
Drug
Lead sponsor
Ronald Hoffman
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 21, 2026, 2:09 PM EDT